D Tang, P Comish, R Kang - PLoS pathogens, 2020 - journals.plos.org
Severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) is a novel coronavirus that has caused a worldwide pandemic of the human respiratory illness COVID-19, resulting in a …
X Gao, B Qin, P Chen, K Zhu, P Hou, JA Wojdyla… - … Pharmaceutica Sinica B, 2021 - Elsevier
The pandemic of coronavirus disease 2019 (COVID-19) is changing the world like never before. This crisis is unlikely contained in the absence of effective therapeutics or vaccine …
A Dashti, S Sukkestad, AM Horner, M Neja, Z Siddiqi… - Nature Medicine, 2023 - nature.com
The main barrier to HIV cure is a persistent reservoir of latently infected CD4+ T cells harboring replication-competent provirus that fuels rebound viremia upon antiretroviral …
Y Kim, JL Anderson, SR Lewin - Cell host & microbe, 2018 - cell.com
Despite the success of antiretroviral therapy (ART), there is currently no HIV cure and treatment is life long. HIV persists during ART due to long-lived and proliferating latently …
Rare CD4 T cells that contain HIV under antiretroviral therapy represent an important barrier to HIV cure,–, but the infeasibility of isolating and characterizing these cells in their natural …
Y Lei, L Tang, Q Chen, L Wu, W He, D Tu… - Nature …, 2022 - nature.com
Nonalcoholic steatohepatitis (NASH) has been linked with the gut-liver axis. Here, we investigate the potential for repurposing disulfiram (DSF), a drug commonly used to treat …
Antiretroviral therapy is not curative. Given the challenges in providing lifelong therapy to a global population of more than 35 million people living with HIV, there is intense interest in …
R Fromentin, W Bakeman, MB Lawani, G Khoury… - PLoS …, 2016 - journals.plos.org
HIV persists in a small pool of latently infected cells despite antiretroviral therapy (ART). Identifying cellular markers expressed at the surface of these cells may lead to novel …
ME Wong, A Jaworowski, AC Hearps - Frontiers in immunology, 2019 - frontiersin.org
In people living with HIV (PLWH) who are failing or unable to access combination antiretroviral therapy (cART), monocytes and macrophages are important drivers of …